000			02238 a2200649 4500
005			20250517152333.0
264		0	_c20170821
008			201708s 0 0 eng d
022			_a1879-0852
024	7		_a10.1016/j.ejca.2017.03.023 _2doi
040			_aNLM _beng _cNLM
100	1		_aStintzing, S
245	0	0	_aImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. _h[electronic resource]
260			_bEuropean journal of cancer (Oxford, England : 1990) _c07 2017
300			_a50-60 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBevacizumab _xadministration & dosage
650	0	4	_aCamptothecin _xadministration & dosage
650	0	4	_aCetuximab _xadministration & dosage
650	0	4	_aColorectal Neoplasms _xdrug therapy
650	0	4	_aExons _xgenetics
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aLeucovorin _xadministration & dosage
650	0	4	_aLiver Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation _xgenetics
650	0	4	_aProto-Oncogene Proteins B-raf _xgenetics
650	0	4	_aProto-Oncogene Proteins p21(ras) _xgenetics
650	0	4	_aRetrospective Studies
650	0	4	_aTreatment Outcome
700	1		_aMiller-Phillips, L
700	1		_aModest, D P
700	1		_aFischer von Weikersthal, L
700	1		_aDecker, T
700	1		_aKiani, A
700	1		_aVehling-Kaiser, U
700	1		_aAl-Batran, S-E
700	1		_aHeintges, T
700	1		_aKahl, C
700	1		_aSeipelt, G
700	1		_aKullmann, F
700	1		_aStauch, M
700	1		_aScheithauer, W
700	1		_aHeld, S
700	1		_aMoehler, M
700	1		_aJagenburg, A
700	1		_aKirchner, T
700	1		_aJung, A
700	1		_aHeinemann, V
773	0		_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 79 _gp. 50-60
856	4	0	_uhttps://doi.org/10.1016/j.ejca.2017.03.023 _zAvailable from publisher's website
999			_c27133761 _d27133761